Alison Birtle, MD
ESMO 2018: We have effective therapies – now we need to find their right sequence
Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, shares her insights on ESMO’s developments in prostate cancer.
Inhalte des Videos
00:00 A trend in favor of putting cabazitaxel before abiraterone or enzalutamide in sequence for poor prognosis of metastatic castration-resistant prostate cancer (Chi KN et al.). 02:39 Four cycles of docetaxel and estramustine reduces death in men with high-risk localized prostate cancer treated with goserelin (GETUG-12; Fizazi K et al.). 03:58 Interesting, but not practice-changing: a phase-III trial investigating the combination of radium-223 and abiraterone for bone-predominant metastatic castration-resistant prostate cancer was negative (ERA-223; Smith MR et al.). 04:20 Prospective ESMO highlights on bladder cancer 05:00 The STAMPEDE trial will be practice-changing (Parker CC et al.) 05:50 Sequence and consequence in prostate cancer: “I would give my second-line therapy first.”Chi KN et al., A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #792O
Fizazi K et al., Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Abstract #791O
Smith MR et al., ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Abstract # LBA30
Parker CC et al., Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476). Abstract #LBA5_PR
De Wit R et al., Pembrolizumab for High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. Abstract #864O
Petrylak I et al., RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Abstract # 865PD
